NBT Bank N A NY Reduces Holdings in Zoetis Inc. (NYSE:ZTS)

NBT Bank N A NY lowered its position in Zoetis Inc. (NYSE:ZTS) by 39.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,134 shares of the company’s stock after selling 4,034 shares during the period. NBT Bank N A NY’s holdings in Zoetis were worth $1,063,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. Webster Bank N. A. boosted its holdings in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares in the last quarter. Private Wealth Management Group LLC purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $33,000. Gladius Capital Management LP purchased a new position in shares of Zoetis in the 4th quarter worth about $40,000. Neo Ivy Capital Management bought a new stake in Zoetis during the 4th quarter valued at about $40,000. Finally, LRI Investments LLC bought a new position in shares of Zoetis in the first quarter worth approximately $43,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS traded up $0.60 on Friday, reaching $183.49. 2,328,501 shares of the company’s stock traded hands, compared to its average volume of 2,678,988. The stock has a 50-day simple moving average of $179.83 and a 200-day simple moving average of $174.60. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The firm has a market cap of $83.73 billion, a PE ratio of 35.35, a P/E/G ratio of 2.78 and a beta of 0.86. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter last year, the company earned $1.41 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. Equities research analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. BTIG Research boosted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. HSBC reduced their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 price target on shares of Zoetis in a research report on Tuesday. The Goldman Sachs Group cut their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $217.11.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.